Keck School Faculty

Detection and treatment of Alzheimer's disease in its preclinical stage Nat Aging. 2023 May; 3(5):520-531. . View in PubMed

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12431. . View in PubMed

Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations Alzheimers Dement. 2023 Apr; 19(4):1549-1557. . View in PubMed

The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease Alzheimers Dement. 2023 Apr; 19(4):1227-1233. . View in PubMed

Novel CYP1B1-RMDN2 Alzheimer's disease locus identified by genome-wide association analysis of cerebral tau deposition on PET medRxiv. 2023 Mar 22. . View in PubMed

Expectations and clinical meaningfulness of randomized controlled trials Alzheimers Dement. 2023 Feb 07. . View in PubMed

Natural cubic splines for the analysis of Alzheimer's clinical trials Pharm Stat. 2023 Jan 10. . View in PubMed

Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials Alzheimers Dement. 2023 02; 19(2):696-707. . View in PubMed

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4 Alzheimers Dement. 2023 01; 19(1):307-317. . View in PubMed

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab J Prev Alzheimers Dis. 2023; 10(2):171-177. . View in PubMed

Lecanemab in Early Alzheimer's Disease N Engl J Med. 2023 01 05; 388(1):9-21. . View in PubMed

Tau positron emission tomography in preclinical Alzheimer's disease Brain. 2023 02 13; 146(2):700-711. . View in PubMed

Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment Alzheimers Res Ther. 2023 05 02; 15(1):88. . View in PubMed

Neurodegener Dis Manag. 2023 03 30. . View in PubMed

Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease J Alzheimers Dis. 2023; 92(1):95-107. . View in PubMed

Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review Ageing Res Rev. 2022 Dec; 82:101777. . View in PubMed

Designing the next-generation clinical care pathway for Alzheimer's disease Nat Aging. 2022 Aug; 2(8):692-703. . View in PubMed

Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers Alzheimers Dement. 2022 Jun 29. . View in PubMed

Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trials JAMIA Open. 2022 Apr; 5(1):ooac008. . View in PubMed

ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trails JAMIA Open. 2022 Apr; 5(1):ooab119. . View in PubMed

Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2022 Feb 25. . View in PubMed

The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary Neurodegener Dis Manag. 2022 10; 12(5):221-229. . View in PubMed

Early-stage Alzheimer disease: getting trial-ready Nat Rev Neurol. 2022 07; 18(7):389-399. . View in PubMed

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum Alzheimers Dement. 2022 07; 18(7):1370-1382. . View in PubMed

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease Alzheimers Dement. 2022 04; 18(4):824-857. . View in PubMed

State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease Alzheimers Dement. 2022 01; 18(1):159-177. . View in PubMed

Impact of sex and APOE e4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults Alzheimers Dement (Amst). 2022; 14(1):e12271. . View in PubMed

Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology Brain. 2022 10 21; 145(10):3594-3607. . View in PubMed

Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report J Prev Alzheimers Dis. 2022; 9(3):388-392. . View in PubMed

Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study Neurology. 2022 03 29; 98(13):e1327-e1336. . View in PubMed

The Ups and Downs of Amyloid in Alzheimer's J Prev Alzheimers Dis. 2022; 9(1):92-95. . View in PubMed

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial Sci Rep. 2022 01 25; 12(1):1346. . View in PubMed

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease J Prev Alzheimers Dis. 2022; 9(2):197-210. . View in PubMed

Aducanumab: Appropriate Use Recommendations Update J Prev Alzheimers Dis. 2022; 9(2):221-230. . View in PubMed

Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial J Prev Alzheimers Dis. 2022; 9(2):255-261. . View in PubMed

Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. J Prev Alzheimers Dis. 2022; 9(2):231-235. . View in PubMed

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease Alzheimers Res Ther. 2022 04 19; 14(1):54. . View in PubMed

J Prev Alzheimers Dis. 2022; 9(4):569-579. . View in PubMed

Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid J Prev Alzheimers Dis. 2022; 9(4):617-624. . View in PubMed

Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites J Prev Alzheimers Dis. 2022; 9(4):665-671. . View in PubMed

Editorial: We Have Turned the Corner J Prev Alzheimers Dis. 2022; 9(S1):S5-S6. . View in PubMed

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease Nat Med. 2021 Jul; 27(7):1187-1196. . View in PubMed

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology Alzheimers Dement. 2021 12; 17(12):2043-2055. . View in PubMed

The case for low-level BACE1 inhibition for the prevention of Alzheimer disease Nat Rev Neurol. 2021 11; 17(11):703-714. . View in PubMed

The Amyloid-ß Pathway in Alzheimer's Disease Mol Psychiatry. 2021 10; 26(10):5481-5503. . View in PubMed

Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2 J Alzheimers Dis. 2021; 83(2):915-925. . View in PubMed

Editorial: How Will Aducanumab Approval Impact AD Research? J Prev Alzheimers Dis. 2021; 8(4):391-392.. View in PubMed

Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force J Prev Alzheimers Dis. 2021; 8(4):513-519. . View in PubMed

Aducanumab: Appropriate Use Recommendations J Prev Alzheimers Dis. 2021; 8(4):398-410. . View in PubMed

Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies Sleep Adv. 2021; 2(1):zpab015. . View in PubMed

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial JAMA Neurol. 2021 03 01; 78(3):293-301. . View in PubMed

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial JAMA Netw Open. 2021 07 01; 4(7):e2114364. . View in PubMed

The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial J Prev Alzheimers Dis. 2021; 8(1):59-67. . View in PubMed

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study Alzheimers Dement (N Y). 2021; 7(1):e12135. . View in PubMed

Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data J Prev Alzheimers Dis. 2021; 8(3):257-262. . View in PubMed

New Hope for Alzheimer's Disease J Prev Alzheimers Dis. 2021; 8(3):238-239. . View in PubMed

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease J Prev Alzheimers Dis. 2021; 8(3):240-248. . View in PubMed

Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force J Prev Alzheimers Dis. 2021; 8(3):306-312. . View in PubMed

The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program J Prev Alzheimers Dis. 2021; 8(3):286-291. . View in PubMed

Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project Biol Psychiatry. 2021 04 15; 89(8):757-765. . View in PubMed

The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression J Alzheimers Dis. 2021; 80(3):991-1002. . View in PubMed

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering Alzheimers Res Ther. 2021 05 10; 13(1):98. . View in PubMed

Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial Alzheimers Dement (Amst). 2021; 13(1):e12199. . View in PubMed

Detection of ß-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers Brain Commun. 2021; 3(2):fcab008. . View in PubMed

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease Alzheimers Dement. 2020 11; 16(11):1483-1492. . View in PubMed

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials J Neurol Neurosurg Psychiatry. 2020 11; 91(11):1201-1209. . View in PubMed

The search for Alzheimer disease therapeutics - same targets, better trials? Nat Rev Neurol. 2020 11; 16(11):597-598.. View in PubMed

Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach Alzheimers Dement. 2020 05; 16(5):797-803. . View in PubMed

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology J Prev Alzheimers Dis. 2020; 7(4):226-233. . View in PubMed

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview J Prev Alzheimers Dis. 2020; 7(4):208-212. . View in PubMed

Data-Driven Participant Recruitment: Findings from the Alzheimer's Disease Neuroimaging Initiative 3 J Prev Alzheimers Dis. 2020; 7(2):122-127. . View in PubMed

Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business J Prev Alzheimers Dis. 2020; 7(3):195-196. . View in PubMed

Authors response to D Umbricht, letter to the editor referring Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky BusinessThe Journal of Prevention of Alzheimer's Disease, 2020. J Prev Alzheimers Dis. 2020; 7(4):300. . View in PubMed

Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report J Prev Alzheimers Dis. 2020; 7(3):152-157. . View in PubMed

BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain Brain. 2020 12 01; 143(12):3816-3826. . View in PubMed

Neuroanatomical spread of amyloid ß and tau in Alzheimer's disease: implications for primary prevention Brain Commun. 2020; 2(1):fcaa007. . View in PubMed

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals JAMA Neurol. 2020 06 01; 77(6):735-745. . View in PubMed

The Future of Anti-Amyloid Trials J Prev Alzheimers Dis. 2020; 7(3):146-151. . View in PubMed

Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study Alzheimers Dement (Amst). 2020; 12(1):e12118. . View in PubMed

Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management Front Neurol. 2020; 11:592302. . View in PubMed

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD) J Prev Alzheimers Dis. 2020; 7(4):219-225. . View in PubMed

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials J Prev Alzheimers Dis. 2020; 7(4):213-218. . View in PubMed

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment JAMA Neurol. 2020 12 01; 77(12):1504-1513. . View in PubMed

Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial JAMA Neurol. 2020 09 01; 77(9):1099-1109. . View in PubMed

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years J Prev Alzheimers Dis. 2020; 7(4):234-241. . View in PubMed

Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease JAMA Neurol. 2020 10 01; 77(10):1288-1298. . View in PubMed

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2019 Oct 01; 76(10):1219-1229. . View in PubMed

Predicting the course of Alzheimer's progression Brain Inform. 2019 Jun 28; 6(1):6. . View in PubMed

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease N Engl J Med. 2019 Apr 11; 380(15):1408-1420. . View in PubMed

Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults Neurobiol Aging. 2019 10; 82:110-119. . View in PubMed

Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study Alzheimers Dement. 2019 09; 15(9):1208-1217. . View in PubMed

A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 05; 15(5):615-624. . View in PubMed

Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention CNS Drugs. 2019 02; 33(2):99-106. . View in PubMed

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. 2019 01; 15(1):106-152. . View in PubMed

Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2019; 6(3):157-163. . View in PubMed

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease J Prev Alzheimers Dis. 2019; 6(4):228-231. . View in PubMed

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018 J Prev Alzheimers Dis. 2019; 6(3):198-203. . View in PubMed

Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability Neuroimage Clin. 2019; 21:101574. . View in PubMed

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease Alzheimers Dement (N Y). 2019; 5:308-318. . View in PubMed

What Next in AD Drug Development? J Prev Alzheimers Dis. 2019; 6(3):150.. View in PubMed

Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report J Prev Alzheimers Dis. 2019; 6(3):169-173. . View in PubMed

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force J Prev Alzheimers Dis. 2019; 6(3):164-168. . View in PubMed

Unsuccessful trials of therapies for Alzheimer's disease Lancet. 2019 01 05; 393(10166):29. . View in PubMed

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease N Engl J Med. 2019 04 11; 380(15):1483-1485. . View in PubMed

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease Alzheimers Res Ther. 2019 08 07; 11(1):68. . View in PubMed

Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial Alzheimers Dement. 2018 11; 14(11):1397-1405. . View in PubMed

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial PLoS Med. 2018 09; 15(9):e1002660. . View in PubMed

Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials Alzheimers Dement. 2018 08; 14(8):1077-1087. . View in PubMed

What We Learn from the CTAD (Clinical Trials Alzheimer's Disease) 2018 J Prev Alzheimers Dis. 2018; 5(4):214-215. . View in PubMed

Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2018; 5(2):98-102. . View in PubMed

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease J Prev Alzheimers Dis. 2018; 5(1):8-14. . View in PubMed

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative Neurodegener Dis. 2018; 18(4):173-190. . View in PubMed

J Prev Alzheimers Dis. 2018; 5(3):171-174. . View in PubMed

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement (Amst). 2018; 10:657-668. . View in PubMed

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease N Engl J Med. 2018 05 03; 378(18):1691-1703. . View in PubMed

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease Alzheimers Dement (N Y). 2018; 4:46-53. . View in PubMed

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3 J Prev Alzheimers Dis. 2018; 5(3):184-187. . View in PubMed

Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force J Prev Alzheimers Dis. 2018; 5(2):103-109. . View in PubMed

Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? J Nutr Health Aging. 2018; 22(8):982-998.. View in PubMed

Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2018 01 16; 90(3):145. . View in PubMed

Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2018 07 01; 75(7):834-841. . View in PubMed

Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease Neurobiol Aging. 2017 Dec; 60:92-103. . View in PubMed

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß Alzheimers Dement. 2017 Sep; 13(9):1004-1012. . View in PubMed

On the path to 2025: understanding the Alzheimer's disease continuum Alzheimers Res Ther. 2017 Aug 09; 9(1):60. . View in PubMed

A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2017 May 02; 88(18):1768-1775. . View in PubMed

Randomized controlled trials in mild cognitive impairment: Sources of variability Neurology. 2017 May 02; 88(18):1751-1758. . View in PubMed

Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals Brain. 2017 May 01; 140(5):1499-1512. . View in PubMed

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement Alzheimers Dement. 2017 May; 13(5):561-571. . View in PubMed

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials Alzheimers Dement. 2017 Apr; 13(4):e1-e85. . View in PubMed

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report Alzheimers Dement (N Y). 2017 06; 3(2):177-188. . View in PubMed

Elevated Brain Amyloid in Cognitively Normal Individuals-Reply JAMA. 2017 10 10; 318(14):1393-1394. . View in PubMed

The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults J Alzheimers Dis. 2017; 60(2):427-437. . View in PubMed

Statistical properties of continuous composite scales and implications for drug development J Biopharm Stat. 2017; 27(6):1104-1114. . View in PubMed

Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism J Prev Alzheimers Dis. 2017; 4(4):211-212. . View in PubMed

Editorial: Collaborative Efforts to Prevent Alzheimer's Disease J Nutr Health Aging. 2017; 21(10):1072-1074. . View in PubMed

EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials J Prev Alzheimers Dis. 2017; 4(2):116-124. . View in PubMed

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease J Neuroinflammation. 2017 01 03; 14(1):1. . View in PubMed

Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment J Alzheimers Dis. 2017; 56(1):229-237. . View in PubMed

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons JAMA. 2017 06 13; 317(22):2305-2316. . View in PubMed

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease BMC Med Genomics. 2017 05 24; 10(Suppl 1):29. . View in PubMed

Cross-validation of optimized composites for preclinical Alzheimer's disease Alzheimers Dement (N Y). 2017 Jan; 3(1):123-129. . View in PubMed

Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network J Prev Alzheimers Dis. 2016 Jun; 3(2):114-120. . View in PubMed

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease Alzheimers Dement (N Y). 2016 Jun; 2(2):131-139. . View in PubMed

Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial Neurology. 2016 May 31; 86(22):2071-6. . View in PubMed

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria Alzheimers Dement. 2016 Mar; 12(3):292-323. . View in PubMed

The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. . View in PubMed

Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. . View in PubMed

Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment Neurobiol Aging. 2016 12; 48:172-181. . View in PubMed

Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials Alzheimers Dement. 2016 05; 12(5):598-603. . View in PubMed

Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials Alzheimers Dement. 2016 05; 12(5):631-2. . View in PubMed

JPAD Is Moving Fast J Prev Alzheimers Dis. 2016; 3(1):3-4. . View in PubMed

CAP--advancing the evaluation of preclinical Alzheimer disease treatments Nat Rev Neurol. 2016 Jan; 12(1):56-61. . View in PubMed

Registries and Cohorts to Accelerate Early Phase Alzheimer's TrialsA Report from the E. U. /U. S. Clinical Trials in Alzheimer's Disease Task Force. J Prev Alzheimers Dis. 2016; 3(2):68-74. . View in PubMed

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease BMC Med Genomics. 2016 08 12; 9 Suppl 1:30. . View in PubMed

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease Alzheimers Res Ther. 2016 06 30; 8:25. . View in PubMed

Drug development in Alzheimer's disease: the path to 2025 Alzheimers Res Ther. 2016 09 20; 8:39. . View in PubMed

Global Alzheimer's Platform Trial Ready Cohorts for the Prevention of Alzheimer's Dementia J Prev Alzheimers Dis. 2016; 3(4):185-187. . View in PubMed

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults JAMA Neurol. 2016 06 01; 73(6):721-32. . View in PubMed

Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology Neurology. 2016 05 17; 86(20):1887-96. . View in PubMed

Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease J Prev Alzheimers Dis. 2016; 3(3):138-144. . View in PubMed

A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS) J Prev Alzheimers Dis. 2015 Dec 01; 2(4):227-241. . View in PubMed

APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern Alzheimers Dement. 2015 Dec; 11(12):1417-1429. . View in PubMed

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neurology. 2015 Oct 20; 85(16):1383-91. . View in PubMed

FASTKD2 is associated with memory and hippocampal structure in older adults Mol Psychiatry. 2015 Oct; 20(10):1197-204. . View in PubMed

GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP Brain. 2015 Oct; 138(Pt 10):3076-88. . View in PubMed

The transitional association between ß-amyloid pathology and regional brain atrophy Alzheimers Dement. 2015 Oct; 11(10):1171-9. . View in PubMed

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. . View in PubMed

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 35 years. Alzheimers Dement (N Y). 2015 Sep; 1(2):111-121. . View in PubMed

Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease Alzheimers Dement. 2015 Sep; 11(9):1080-9. . View in PubMed

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions Lancet Neurol. 2015 Sep; 14(9):926-944. . View in PubMed

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials Alzheimers Dement. 2015 Sep; 11(9):1069-79. . View in PubMed

The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding Alzheimers Dement. 2015 Jul; 11(7):823-31. . View in PubMed

HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study Mol Psychiatry. 2015 Jul; 20(7):867-73. . View in PubMed

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans Alzheimers Dement. 2015 Jul; 11(7):734-9. . View in PubMed

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Alzheimers Dement. 2015 Jul; 11(7):865-84. . View in PubMed

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans Alzheimers Dement. 2015 Jul; 11(7):772-91. . View in PubMed

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception Alzheimers Dement. 2015 Jun; 11(6):e1-120. . View in PubMed

Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force J Prev Alzheimers Dis. 2015 Jun; 2(2):128-135. . View in PubMed

Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls JAMA Neurol. 2015 May; 72(5):554-60. . View in PubMed

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease Ann Clin Transl Neurol. 2015 May; 2(5):534-47. . View in PubMed

Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument JAMA Neurol. 2015 Apr; 72(4):446-54. . View in PubMed

Advances in Alzheimer's disease drug development BMC Med. 2015 Mar 25; 13:62. . View in PubMed

Brain structure and function as mediators of the effects of amyloid on memory Neurology. 2015 Mar 17; 84(11):1136-44. . View in PubMed

Protective variant for hippocampal atrophy identified by whole exome sequencing Ann Neurol. 2015 Mar; 77(3):547-52. . View in PubMed

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome Front Behav Neurosci. 2015; 9:239. . View in PubMed

Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment Neurobiol Aging. 2015 Jan; 36(1):273-82. . View in PubMed

Alzheimers Res Ther. 2015; 7(1):36. . View in PubMed

Alzheimer's disease progression by geographical region in a clinical trial setting Alzheimers Res Ther. 2015; 7(1):43. . View in PubMed

Cognitive/Clinical Endpoints for Pre-Dementia AD Trials J Prev Alzheimers Dis. 2015; 2(2):82-84. . View in PubMed

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease J Alzheimers Dis. 2015; 47(1):205-14. . View in PubMed

Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia J Alzheimers Dis. 2015; 43(3):949-55. . View in PubMed

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials Alzheimers Res Ther. 2015; 7(1):39. . View in PubMed

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. . View in PubMed

The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations J Prev Alzheimers Dis. 2014 Dec; 1(3):181-202. . View in PubMed

Estimating long-term multivariate progression from short-term data Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. . View in PubMed

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. . View in PubMed

The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. . View in PubMed

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline JAMA Neurol. 2014 Aug; 71(8):961-70. . View in PubMed

Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis Neurology. 2014 Jul 15; 83(3):253-60. . View in PubMed

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. . View in PubMed

Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. . View in PubMed

Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease Neurology. 2014 Apr 29; 82(17):1536-42. . View in PubMed

Serum brain-derived neurotrophic factor and the risk for dementia JAMA. 2014 Apr 23-30; 311(16):1684-5. . View in PubMed

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020 Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. . View in PubMed

The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13.. View in PubMed

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatry. 2014 Mar; 19(3):351-7. . View in PubMed

Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. . View in PubMed

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med. 2014 Jan 23; 370(4):311-21. . View in PubMed

Effect of TTP488 in patients with mild to moderate Alzheimer's disease BMC Neurol. 2014 Jan 15; 14:12. . View in PubMed

EU/U. S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alzheimers Dis. 2014; 1(2):110-116. . View in PubMed

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease N Engl J Med. 2014 04 10; 370(15):1460. . View in PubMed

Association of plasma and cortical amyloid beta is modulated by APOE e4 status Alzheimers Dement. 2014 Jan; 10(1):e9-e18. . View in PubMed

Journal of Prevention of Alzheimer's Disease (JPAD): Building a "Fleet" Against Alzheimer's Disease J Prev Alzheimers Dis. 2014; 1(1):2-3. . View in PubMed

Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. . View in PubMed

Detecting When "Quality of Life" Has Been "Enhanced": Estimating Change in Quality of Life Ratings Open J Philos. 2013 Nov 01; 3(4A):24-31. . View in PubMed

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris). 2013 Oct; 169(10):737-43. . View in PubMed

Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. . View in PubMed

Developing dementia prevention trials: baseline report of the Home-Based Assessment study Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. . View in PubMed

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement. 2013 Sep; 9(5):e111-94. . View in PubMed

The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. . View in PubMed

Mild cognitive impairment due to Alzheimer disease in the community Ann Neurol. 2013 Aug; 74(2):199-208. . View in PubMed

A phase 3 trial of semagacestat for treatment of Alzheimer's disease N Engl J Med. 2013 Jul 25; 369(4):341-50. . View in PubMed

Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics Mol Psychiatry. 2013 Jul; 18(7):739. . View in PubMed

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement. 2013 Jul; 9(4):438-44. . View in PubMed

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly Neuropsychology. 2013 Jul; 27(4):391-401. . View in PubMed

Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment Mol Psychiatry. 2013 Jul; 18(7):781-7. . View in PubMed

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease Nat Rev Drug Discov. 2013 Apr; 12(4):324. . View in PubMed

Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. . View in PubMed

Health-related resource use and costs in elderly adults with and without mild cognitive impairment J Am Geriatr Soc. 2013 Mar; 61(3):396-402. . View in PubMed

Apolipoprotein E epsilon4 does not modulate amyloid-ß-associated neurodegeneration in preclinical Alzheimer disease AJNR Am J Neuroradiol. 2013 Mar; 34(3):505-10. . View in PubMed

Antioxidants for Alzheimer disease-reply JAMA Neurol. 2013 Feb; 70(2):270-1. . View in PubMed

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol. 2013 Feb; 12(2):207-16. . View in PubMed

Effect of study partner on the conduct of Alzheimer disease clinical trials Neurology. 2013 Jan 15; 80(3):282-8. . View in PubMed

Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging. 2013 Jan; 17(1):49-50.. View in PubMed

Semagacestat for treatment of Alzheimer's disease N Engl J Med. 2013 10 24; 369(17):1661. . View in PubMed

Early indications of future cognitive decline: stable versus declining controls PLoS One. 2013; 8(9):e74062. . View in PubMed

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) Front Aging Neurosci. 2013; 5:11. . View in PubMed

Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel PLoS One. 2013; 8(7):e70269. . View in PubMed

Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks Brain Imaging Behav. 2012 Dec; 6(4):634-48. . View in PubMed

Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol. 2012 Oct; 72(4):578-86. . View in PubMed

Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network Clin Investig (Lond). 2012 Oct 01; 2(10):975-984. . View in PubMed

CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects Cereb Cortex. 2012 Sep; 22(9):1993-2004. . View in PubMed

Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med. 2012 Aug 30; 367(9):795-804. . View in PubMed

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease Alzheimers Dement. 2012 Jul; 8(4):261-71. . View in PubMed

Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials Arch Neurol. 2012 Jul; 69(7):901-5. . View in PubMed

Shapes of the trajectories of 5 major biomarkers of Alzheimer disease Arch Neurol. 2012 Jul; 69(7):856-67. . View in PubMed

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. . View in PubMed

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch Neurol. 2012 Jul; 69(7):836-41. . View in PubMed

Considerations in the design of clinical trials for cognitive aging J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. . View in PubMed

Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau Arch Neurol. 2012 Jun; 69(6):709-13. . View in PubMed

Nonlinear time course of brain volume loss in cognitively normal and impaired elders Neurobiol Aging. 2012 May; 33(5):845-55. . View in PubMed

Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology J Nutr Health Aging. 2012 Apr; 16(4):339-45. . View in PubMed

Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. . View in PubMed

Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials J Nutr Health Aging. 2012 Apr; 16(4):360-4. . View in PubMed

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. . View in PubMed

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. . View in PubMed

Incidence of new-onset seizures in mild to moderate Alzheimer disease Arch Neurol. 2012 Mar; 69(3):368-72. . View in PubMed

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. . View in PubMed

Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial Neurology. 2012 Jan 10; 78(2):91-101. . View in PubMed

Down's syndrome and Alzheimer's disease: towards secondary prevention Nat Rev Drug Discov. 2012 09; 11(9):655-6. . View in PubMed

Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost" PLoS One. 2012; 7(2):e30019. . View in PubMed

Biomarkers for Alzheimer's disease therapeutic trials Prog Neurobiol. 2011 Dec; 95(4):579-93. . View in PubMed

Prevention trials in Alzheimer's disease: an EU-US task force report Prog Neurobiol. 2011 Dec; 95(4):594-600. . View in PubMed

Evidence for ordering of Alzheimer disease biomarkers Arch Neurol. 2011 Dec; 68(12):1526-35. . View in PubMed

Clinical trial methodologies for disease-modifying therapeutic approaches Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. . View in PubMed

Testing the right target and right drug at the right stage Sci Transl Med. 2011 Nov 30; 3(111):111cm33. . View in PubMed

Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment Transl Psychiatry. 2011 Nov 15; 1:e54. . View in PubMed

Longitudinal change of biomarkers in cognitive decline Arch Neurol. 2011 Oct; 68(10):1257-66. . View in PubMed

Amyloid-ß associated volume loss occurs only in the presence of phospho-tau Ann Neurol. 2011 Oct; 70(4):657-61. . View in PubMed

Factors affecting Aß plasma levels and their utility as biomarkers in ADNI Acta Neuropathol. 2011 Oct; 122(4):401-13. . View in PubMed

Chronic divalproex sodium use and brain atrophy in Alzheimer disease Neurology. 2011 Sep 27; 77(13):1263-71. . View in PubMed

The relative efficiency of time-to-threshold and rate of change in longitudinal data Contemp Clin Trials. 2011 Sep; 32(5):685-93. . View in PubMed

Q&A: The Alzheimer's Disease Neuroimaging Initiative BMC Med. 2011 Sep 01; 9:101. . View in PubMed

Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment Alzheimers Dement. 2011 Sep; 7(5):514-20. . View in PubMed

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology. 2011 Aug 09; 77(6):556-63. . View in PubMed

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. . View in PubMed

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. . View in PubMed

AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials Alzheimers Dement. 2011 Jul; 7(4):e109-17. . View in PubMed

Commentary on "Biomarkers in Alzheimer's disease drug development" Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. . View in PubMed

Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition Brain. 2011 May; 134(Pt 5):1479-92. . View in PubMed

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 2011 May; 7(3):280-92. . View in PubMed

A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology. 2011 Apr 19; 76(16):1389-94. . View in PubMed

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. . View in PubMed

Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. . View in PubMed

Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010 Alzheimers Dement. 2011 Mar; 7(2):127-32. . View in PubMed

Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid Alzheimers Dement. 2011 Mar; 7(2):133-41. . View in PubMed

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch Med Sci. 2011 Feb; 7(1):102-11. . View in PubMed

Report of the task force on designing clinical trials in early (predementia) AD Neurology. 2011 Jan 18; 76(3):280-6. . View in PubMed

A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice PLoS One. 2011 Jan 17; 6(1):e16259. . View in PubMed

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Alzheimers Res Ther. 2011 Jan 06; 3(1):1. . View in PubMed

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Neurology. 2011 Jan 04; 76(1):69-79. . View in PubMed

A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease J Alzheimers Dis. 2011; 24 Suppl 2:5-16. . View in PubMed

Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects Neurology. 2010 Nov 30; 75(22):1976-81. . View in PubMed

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA. 2010 Nov 03; 304(17):1903-11. . View in PubMed

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain. 2010 Nov; 133(11):3336-48. . View in PubMed

Dependence as a unifying construct in defining Alzheimer's disease severity Alzheimers Dement. 2010 Nov; 6(6):482-93. . View in PubMed

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment Alzheimers Dement. 2010 Sep; 6(5):412-9. . View in PubMed

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects Neurobiol Aging. 2010 Aug; 31(8):1284-303. . View in PubMed

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study Neurobiol Aging. 2010 Aug; 31(8):1340-54. . View in PubMed

Comparing predictors of conversion and decline in mild cognitive impairment Neurology. 2010 Jul 20; 75(3):230-8. . View in PubMed

Serial MRI and CSF biomarkers in normal aging, MCI, and AD Neurology. 2010 Jul 13; 75(2):143-51. . View in PubMed

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. . View in PubMed

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol. 2010 Jun; 223(2):334-46. . View in PubMed

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans Alzheimers Dement. 2010 May; 6(3):239-46. . View in PubMed

3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI Hum Brain Mapp. 2010 May; 31(5):786-97. . View in PubMed

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects Alzheimers Dement. 2010 May; 6(3):230-8. . View in PubMed

The Alzheimer's disease neuroimaging initiative: progress report and future plansAlzheimers Dement. 2010 May; 6(3):202-11. e7. . View in PubMed

NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. . View in PubMed

Therapeutics for cognitive aging Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. . View in PubMed

Pre-dementia Alzheimer's trials: overview J Nutr Health Aging. 2010 Apr; 14(4):294. . View in PubMed

Early Alzheimer's trials: new developments J Nutr Health Aging. 2010 Apr; 14(4):293. . View in PubMed

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 Alzheimers Dement. 2010 Mar; 6(2):89-97. . View in PubMed

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease Ann Neurol. 2010 Mar; 67(3):308-16. . View in PubMed

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology. 2010 Jan 19; 74(3):201-9. . View in PubMed

What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty Curr Gerontol Geriatr Res. 2010; 510614. . View in PubMed

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol. 2010 Jan; 9(1):119-28. . View in PubMed

Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome Sci Transl Med. 2009 Nov 18; 1(7):7ra17. . View in PubMed

MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. . View in PubMed

The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. . View in PubMed

No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease Neurobiol Aging. 2009 Aug; 30(8):1327-8. . View in PubMed

Alzheimer's disease therapeutic research: the path forward Alzheimers Res Ther. 2009 Jul 09; 1(1):2. . View in PubMed

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study J Nutr Health Aging. 2009 Jun; 13(6):550-7. . View in PubMed

Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21.. View in PubMed

The net effect of alternative allocation ratios on recruitment time and trial cost Clin Trials. 2009 Apr; 6(2):126-32. . View in PubMed

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience J Nutr Health Aging. 2009 Apr; 13(4):370-2. . View in PubMed

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol. 2009 Apr; 65(4):403-13. . View in PubMed

Interpreting biomarker data in therapeutic trials J Nutr Health Aging. 2009 Apr; 13(4):337-8. . View in PubMed

Commentary on "a roadmap for the prevention of dementia IILeon Thal Symposium 2008. " Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. . View in PubMed

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. . View in PubMed

Recent developments in Alzheimer's disease therapeutics BMC Med. 2009 Feb 19; 7:7. . View in PubMed

Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo Neurosci Lett. 2009 Jan 23; 450(1):51-5. . View in PubMed

Agreement in cognitive and clinical assessments in Alzheimer's disease Dement Geriatr Cogn Disord. 2009; 27(4):344-52. . View in PubMed

Plasma urate and progression of mild cognitive impairment Neurodegener Dis. 2009; 6(1-2):23-8. . View in PubMed

Methodological issues in primary prevention trials for neurodegenerative dementia J Alzheimers Dis. 2009; 16(2):235-70. . View in PubMed

Applications of neuroimaging to disease-modification trials in Alzheimer's disease Behav Neurol. 2009; 21(1):129-36. . View in PubMed

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA. 2008 Oct 15; 300(15):1774-83. . View in PubMed

Amyloid-based therapeutics: findings translated into novel treatments CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. . View in PubMed

Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. . View in PubMed

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol. 2008 Aug; 65(8):1031-8. . View in PubMed

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet. 2008 Jul 19; 372(9634):207-15. . View in PubMed

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model Brain Res. 2008 Jun 24; 1216:92-103. . View in PubMed

Tarenflurbil: a shot on goal Lancet Neurol. 2008 Jun; 7(6):468-9. . View in PubMed

Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1.. View in PubMed

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. . View in PubMed

Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo Neurosci Lett. 2008 Apr 25; 435(3):186-9. . View in PubMed

A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. . View in PubMed

An update on huperzine A as a treatment for Alzheimer's disease Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. . View in PubMed

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial Curr Alzheimer Res. 2008 Feb; 5(1):73-82. . View in PubMed

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment Neurology. 2008 Jan 15; 70(3):191-9. . View in PubMed

An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1.. View in PubMed

The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5.. View in PubMed

Leon Thal and the therapeutic age of Alzheimer's disease Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. . View in PubMed

Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration Eur J Neurosci. 2007 Nov; 26(9):2458-68. . View in PubMed

Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006"--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. . View in PubMed

Alzhemed: a potential treatment for Alzheimer's disease Curr Alzheimer Res. 2007 Sep; 4(4):473-8. . View in PubMed

Antibody against C-terminal Abeta selectively elevates plasma Abeta Neuroreport. 2007 Feb 12; 18(3):293-6. . View in PubMed

A simple method to rule out dementia with temporal orientation Alzheimers Dement. 2007 Jan; 3(1):28-32. . View in PubMed

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage J Mol Neurosci. 2007; 31(2):165-70. . View in PubMed

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice J Neurochem. 2006 Dec; 99(6):1555-63. . View in PubMed

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology. 2006 Nov 28; 67(10):1757-63. . View in PubMed

Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach Alzheimers Dement. 2006 Oct; 2(4):303-13. . View in PubMed

ADCS Prevention Instrument Project: overview and initial results Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. . View in PubMed

Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials" Alzheimers Dement. 2006 Oct; 2(4):272-4. . View in PubMed

ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI) Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. . View in PubMed

Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed Alzheimers Dement. 2006 Jul; 2(3):153-4. . View in PubMed

In vivo protein transduction to the CNS Neuroscience. 2006; 139(3):1061-7. . View in PubMed

Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman Chem Biol Interact. 2005 Dec 15; 157-158:239-46. . View in PubMed

Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1.. View in PubMed

One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. . View in PubMed

An Abeta sequestration approach using non-antibody Abeta binding agents Curr Alzheimer Res. 2005 Apr; 2(2):265-8. . View in PubMed

Pharmacologic treatment options in Alzheimer's disease: optimizing disease management J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. . View in PubMed

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP) CNS Drug Rev. 2005; 11(4):353-68. . View in PubMed

Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly Neuroepidemiology. 2005; 24(1-2):110-6. . View in PubMed

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors CNS Drugs. 2005; 19(12):989-96. . View in PubMed

Inflammatory processes and Alzheimer's disease Expert Rev Neurother. 2004 Sep; 4(5):793-8. . View in PubMed

Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant Biochem Biophys Res Commun. 2004 Jul 02; 319(3):733-7. . View in PubMed

Georgetown University School of Medicine Acad Med. 2004 Jul; 79(7 Suppl):S45-50. . View in PubMed

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials Arch Neurol. 2004 Jan; 61(1):59-66. . View in PubMed

Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol. 2003 Jul; 250(7):788-92.. View in PubMed

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA. 2003 Jun 04; 289(21):2819-26. . View in PubMed

NSAIDs and hypertension Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. . View in PubMed

A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. . View in PubMed

Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid J Clin Lab Anal. 2003; 17(1):18-21. . View in PubMed

Anti-inflammatory agents in Alzheimer's disease Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. . View in PubMed

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease Lancet Neurol. 2002 Sep; 1(5):279-84. . View in PubMed

Randomized pilot study of nimesulide treatment in Alzheimer's disease Neurology. 2002 Apr 09; 58(7):1050-4. . View in PubMed

Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. . View in PubMed

Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2 Acta Neuropathol. 2002 Feb; 103(2):157-62. . View in PubMed

Chemistry and biology of eukaryotic iron metabolism Int J Biochem Cell Biol. 2001 Oct; 33(10):940-59. . View in PubMed

Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease Arch Neurol. 2001 Mar; 58(3):487-92. . View in PubMed

Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique Neurosci Lett. 2001 Feb 09; 298(3):191-4. . View in PubMed

Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death Clin Exp Rheumatol. 2001; 19(1 Suppl 22):S7-11. . View in PubMed

Elevated plasma neopterin levels in Alzheimer disease Alzheimer Dis Assoc Disord. 2000 Oct-Dec; 14(4):228-30. . View in PubMed

Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia Arch Neurol. 2000 Aug; 57(8):1153-60. . View in PubMed

Elevated CSF prostaglandin E2 levels in patients with probable AD Neurology. 2000 Jul 25; 55(2):323. . View in PubMed

Anti-inflammatory therapy for Alzheimer's disease Neurobiol Aging. 2000 May-Jun; 21(3):447-8; discussion 451-3. . View in PubMed

A randomized controlled trial of prednisone in Alzheimer's diseaseAlzheimer's Disease Cooperative Study. Neurology. 2000 Feb 08; 54(3):588-93. . View in PubMed

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol. 2000 Jan; 57(1):100-5. . View in PubMed

Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial Acta Neurol Scand Suppl. 2000; 176:85-9. . View in PubMed

Increased levels of tau-like protein in patients with Down syndrome Neurosci Lett. 1999 Nov 19; 275(3):159-62. . View in PubMed

Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2 Am J Pathol. 1999 Sep; 155(3):995-1004. . View in PubMed

Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease J Neurosci Res. 1999 Aug 01; 57(3):295-303. . View in PubMed

Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity J Cell Biochem. 1999 Jun 01; 73(3):303-11. . View in PubMed

Iron metabolism Curr Opin Chem Biol. 1999 Apr; 3(2):200-6. . View in PubMed

HLA-DR4 influences glial activity in Alzheimer's disease hippocampus J Neurol Sci. 1998 Nov 26; 161(1):66-9. . View in PubMed

Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain Neuroscience. 1998 Nov; 87(2):319-24. . View in PubMed

Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death J Neuroimmunol. 1998 Aug 14; 89(1-2):142-9. . View in PubMed

Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old Am J Psychiatry. 1998 May; 155(5):698-700. . View in PubMed

Glucocorticoids in Alzheimer's diseaseThe story so far. Drugs Aging. 1998 Jan; 12(1):1-6. . View in PubMed

Transferrin, the transferrin receptor, and the uptake of iron by cells Met Ions Biol Syst. 1998; 35:585-631. . View in PubMed

A kinetically active site in the C-lobe of human transferrin Biochemistry. 1997 Sep 09; 36(36):11036-43. . View in PubMed

The search for disease-modifying treatment for Alzheimer's disease Neurology. 1997 May; 48(5 Suppl 6):S35-41. . View in PubMed

Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease Exp Neurol. 1997 Apr; 144(2):339-49. . View in PubMed

Selegiline in the treatment of behavioural disturbance in Alzheimer's disease Int J Geriatr Psychiatry. 1997 Mar; 12(3):319-22. . View in PubMed

Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies Gerontology. 1997; 43(1-2):143-9. . View in PubMed

Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans Infect Immun. 1996 Jul; 64(7):2420-4. . View in PubMed

A pilot study of prednisone in Alzheimer's disease Dementia. 1996 Jul-Aug; 7(4):201-6. . View in PubMed

IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells Brain Res. 1996 Jun 03; 723(1-2):231-4. . View in PubMed

Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression Hepatology. 1996 Jun; 23(6):1512-20. . View in PubMed

Inflammation and Alzheimer disease Mol Chem Neuropathol. 1996 May-Aug; 28(1-3):83-8. . View in PubMed

Informatics and Geriatric Psychiatry Am J Geriatr Psychiatry. 1996 Spring; 4(2):140-151. . View in PubMed

Antinuclear antibodies in multiple sclerosis Neurology. 1995 Dec; 45(12):2299-300;author reply 2300-1. . View in PubMed

Iron release from recombinant N-lobe and mutants of human transferrin Biochemistry. 1995 Nov 07; 34(44):14428-34. . View in PubMed

Uptake of iron from N-terminal half-transferrin by isolated rat hepatocytesEvidence of transferrin-receptor-independent iron uptake. Eur J Biochem. 1995 Aug 15; 232(1):129-33. . View in PubMed

Cryptococcus neoformans melanin and virulence: mechanism of action Infect Immun. 1995 Aug; 63(8):3131-6. . View in PubMed

A pilot study of clonidine plus physostigmine in Alzheimer's disease Dementia. 1994 Sep-Oct; 5(5):243-6. . View in PubMed

Shoulder-hand syndrome in cervical spinal cord injury Paraplegia. 1994 Sep; 32(9):588-92. . View in PubMed

Inflammatory mechanisms in Alzheimer's disease: implications for therapy Am J Psychiatry. 1994 Aug; 151(8):1105-13. . View in PubMed

Primary receptor-recognition site of human transferrin is in the C-terminal lobe J Biol Chem. 1994 Mar 11; 269(10):7110-4. . View in PubMed

Determinants of Length of Stay in Geropsychiatry Am J Geriatr Psychiatry. 1994 Spring; 2(2):165-168. . View in PubMed

The transferrin receptor and the release of iron from transferrin Adv Exp Med Biol. 1994; 356:31-40. . View in PubMed

The anion requirement for iron release from transferrin is preserved in the receptor-transferrin complex Biochemistry. 1993 Aug 17; 32(32):8162-7. . View in PubMed

Continuous wave electron nuclear double resonance spectroscopy Methods Enzymol. 1993; 227:190-231. . View in PubMed

Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease Am J Geriatr Psychiatry. 1993 Summer; 1(3):244-248. . View in PubMed

Trazodone for Behavioral Disturbance in Alzheimer's Disease Am J Geriatr Psychiatry. 1993 Autumn; 1(4):349-350. . View in PubMed

Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line Am J Hematol. 1993 Jan; 42(1):74-80. . View in PubMed

A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease Alzheimer Dis Assoc Disord. 1993; 7(2):98-104. . View in PubMed

Catalysis of the Haber-Weiss reaction by iron-diethylenetriaminepentaacetate J Inorg Biochem. 1992 Dec; 48(4):241-9. . View in PubMed

Neuroleptic malignant syndrome induced by low-dose haloperidol Am J Psychiatry. 1992 Jun; 149(6):844. . View in PubMed

Receptor-induced switch in site-site cooperativity during iron release by transferrin Biochemistry. 1992 Apr 28; 31(16):3963-7. . View in PubMed

GPSYCH: Clinical management software for a Geropsychiatry Division Proc Annu Symp Comput Appl Med Care. 1992; 322-6. . View in PubMed

Entry of iron into cells: a new role for the transferrin receptor in modulating iron release from transferrin Ann Neurol. 1992; 32 Suppl:S62-8. . View in PubMed

Receptor-modulated iron release from transferrin: differential effects on N- and C-terminal sites Biochemistry. 1991 Oct 15; 30(41):9947-52. . View in PubMed

A new role for the transferrin receptor in the release of iron from transferrin Biochemistry. 1991 Jan 15; 30(2):324-8. . View in PubMed

Medical evaluation of the elderly psychiatric patient Mt Sinai J Med. 1991 Jan; 58(1):85-90. . View in PubMed

Ferritin receptors and the role of ferritin in iron transport Targeted Diagn Ther. 1991; 4:339-54. . View in PubMed

Evidence for functional differences between the two sites of rabbit transferrin: effects of serum and carbon dioxide Biochim Biophys Acta. 1990 Apr 09; 1052(1):24-8. . View in PubMed

Release of iron from diferric transferrin in the presence of rat liver plasma membranes: no evidence of a plasma membrane diferric transferrin reductase Biochim Biophys Acta. 1990 Apr 09; 1052(1):29-35. . View in PubMed

Iron toxicosis Int Rev Exp Pathol. 1990; 31:1-46. . View in PubMed

Subcellular localization of ferritin and iron taken up by rat hepatocytes Biochem J. 1989 Sep 01; 262(2):685-8. . View in PubMed

Hypochondriasis in the elderly depressed J Am Geriatr Soc. 1989 Jun; 37(6):507-10. . View in PubMed

Microbial glycolipids: possible virulence factors that scavenge oxygen radicals Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2453-7. . View in PubMed

Pathways in the binding and uptake of ferritin by hepatocytes Biochim Biophys Acta. 1989 Mar 28; 1011(1):40-5. . View in PubMed

Uptake of ferritin and iron bound to ferritin by rat hepatocytes: modulation by apotransferrin, iron chelators and chloroquine Biochim Biophys Acta. 1989 Feb 09; 1010(2):204-9. . View in PubMed

Occult aspiration of a nut in an elderly patient: a case report Am J Forensic Med Pathol. 1988 Jun; 9(2):163-5. . View in PubMed

The binding of molybdate to uteroferrinHyperfine interactions of the binuclear center with 95Mo, 1H, and 2H. J Biol Chem. 1988 Apr 25; 263(12):5757-63. . View in PubMed

Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein Hepatology. 1988 Mar-Apr; 8(2):296-301. . View in PubMed

Spectroscopic and thermodynamic studies on the binding of gadolinium(III) to human serum transferrin Biochemistry. 1988 Feb 09; 27(3):1075-80. . View in PubMed

Iron metabolism in the erythrophagocytosing Kupffer cell Hepatology. 1988 Jan-Feb; 8(1):32-8. . View in PubMed

Iron metabolism in isolated liver cells Ann N Y Acad Sci. 1988; 526:93-100. . View in PubMed

Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma Magn Reson Med. 1987 Oct; 5(4):395-7. . View in PubMed

Interaction of transferrin with iron-loaded rat peritoneal macrophages Br J Haematol. 1986 Feb; 62(2):275-86. . View in PubMed

The novel "g' = 174" EPR spectrum of pink and purple uteroferrin. J Biol Chem. 1980 Dec 10; 255(23):11204-9. . View in PubMed

EPR and other studies of the anion-binding sites of transferrin Ann N Y Acad Sci. 1973 Dec 31; 222:337-46. . View in PubMed

Citrate-mediated exchange of FE3+ among tranferrin molecules Biochem Biophys Res Commun. 1968 Jul 26; 32(2):220-6. . View in PubMed

The stability constants of the Fe3+ conalbumin complexes Biochem Biophys Res Commun. 1968 Feb 26; 30(4):407-13. . View in PubMed

A rapid screening test for deficiency of plasma ceruloplasmin and its value in the diagnosis of Wilson's disease Am J Med. 1960 Apr; 28:550-4. . View in PubMed